Compare
Charles River Laboratories International, Inc. vs Incyte Corp vs Medpace Holdings, Inc. vs Icon PLC
| Latest fiscal year | Charles River Laboratories International, Inc. CRL | Incyte Corp INCY | Medpace Holdings, Inc. MEDP | Icon PLC ICLR |
|---|---|---|---|---|
| Year ended | 2025-12-27 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.02B | $5.14B | $2.53B | $8.25B |
| Revenue growth (YoY) | -0.9% | +21.2% | +20.0% | +0.8% |
| Gross margin | n/a | 92.8% (computed) | n/a | n/a |
| Operating margin | 0.6% | 29.5% | 21.1% | 5.4% |
| Net margin | -3.5% | 25.0% | 17.8% | 2.8% |
| Net income | -$142.16M | $1.29B | $451.12M | $229.34M |
| EPS (Diluted) | -$2.91 | $6.41 | $15.28 | $2.90 |
| Operating cash flow | $737.65M | $1.41B | $713.22M | $1.04B |
| Free cash flow | $518.49M | n/a | $681.87M | $861.99M |
| Cash & equivalents | $213.77M | $3.10B | $497.05M | $647.29M |
| Total assets | $7.14B | $6.96B | $1.98B | $16.27B |
| Total liabilities | $3.92B | $1.79B | $1.52B | $7.08B |
| Shareholders' equity | $3.17B | $5.17B | $459.07M | $9.19B |
| Return on year-end equity | -4.5% | 24.9% | 98.3% | 2.5% |
| Shares outstanding | 49.22M | 198.46M | 28.37M | 76.57M |
Revenue, most recent five fiscal years
| Fiscal year | Charles River Laboratories International, Inc. | Incyte Corp | Medpace Holdings, Inc. | Icon PLC |
|---|---|---|---|---|
| Latest | $4.02B Ended 2025-12-27 | $5.14B Ended 2025-12-31 | $2.53B Ended 2025-12-31 | $8.25B Ended 2025-12-31 |
| 1 year earlier | $4.05B Ended 2024-12-28 | $4.24B Ended 2024-12-31 | $2.11B Ended 2024-12-31 | $8.19B Ended 2024-12-31 |
| 2 years earlier | $4.13B Ended 2023-12-30 | $3.70B Ended 2023-12-31 | $1.89B Ended 2023-12-31 | $8.05B Ended 2023-12-31 |
| 3 years earlier | $3.98B Ended 2022-12-31 | $3.39B Ended 2022-12-31 | $1.46B Ended 2022-12-31 | $7.74B Ended 2022-12-31 |
| 4 years earlier | $3.54B Ended 2021-12-25 | $2.99B Ended 2021-12-31 | $1.14B Ended 2021-12-31 | $5.48B Ended 2021-12-31 |